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TO THE EDITOR
Exposure to solar UVR continues to be a
major contributing factor in the increase
in the incidence of skin cancer. Muta-
genic photoproducts formed in the DNA
of UV-exposed cells, specifically due to
absorption of radiation in the UVB range
of 280–320 nm, include cyclobutane
pyrimidine dimers (CPDs) and pyrimi-
dine (6–4) photoproducts (Rastogi et al.,
2010). The CPDs are the major
contributors to mutations in mammals,
as they are repaired less quickly than
(6–4) photoproducts. Recent studies
suggest that some of the existing UV-
filtering agents can form harmful photo-
degradation products (Hanson et al.,
2006; Mosley et al., 2007; Burnett and
Wang, 2011). Therefore, there is a pres-
sing need for new strategies of photo-
protection to reduce the detrimental
effects of UVR. To this end, we
adopted a bio-mimetic approach for
photoprotection using acyclothymidine
dinucleosides (aTds).
It has been shown that topical applica-
tion of thymidine dinucleotides resulted
in DNA photoprotection (Goukassian
et al., 2004, 2012; Arad et al., 2008).
The aTds eliminate the complex and
unstable phosphate-linked diribofura-
nosyl moieties in oligonucleotides and
are inexpensive to prepare (Figure 1a). In
addition, they retain the ability to offer
photoprotection by mimicking the vul-
nerable adjacent thymidine sequences
present in DNA molecules.
We have recently reported that aTd
protects plasmid and cellular DNA
(in vitro) from UVR while undergoing a
photocatalyzed [2þ2] cycloaddition to
form UV non-cytotoxic cyclobutane
dimers (Raza et al., 2013). These
non-cytotoxic mimetics of naturally
occurring DNA dithymidine sequences
have UV adsorption spectra comparable
to native DNA thymidine and are
similar to the naturally occurring
excised DNA thymine dimers. We
have now examined the efficacy of
aTd to reduce the incidence of cellular
DNA thymine dimer formation after
exposure to UVB irradiation in three
separate experiments using the SKH1-E
hairless mouse model (Crl:SKH1-Hr hr
strain code 477, Charles River Labora-
tories International, Wilmington, MA)
and human abdominal skin explants.
For all studies, detailed methodology
can be found in accompanying Supple-
mentary Information online.
ACUTE UVB EXPOSURE
Dorsal skin of immunocompetent, hair-
less SKH1-E mice and humanAccepted article preview online 12 August 2013; published online 19 September 2013
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abdominal skin explants (University of
Minnesota BioNet Tissue Procurement
Facility, Minneapolis, MN) were evalu-
ated for thymine dimer formation after
topical treatment with 0.1 ml of cream
vehicle or 0.1 ml of aTd (5% w/w) in
cream vehicle 20 minutes before irradia-
tion using UVB (only) bulbs. This preli-
minary study was conducted using UVB
bulbs (Top Bulb, East Chicago, IN) with
a peak emission at 306 nm. UVB dose
was metered at 180 mJ cm 2 using an
ILT1700 light meter with an SED 240
probe (International Light Technologies,
Peabody, MA).
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Figure 1. Acyclothymidine dinucleoside (aTd) topical treatment is photoprotective against UVB irradiation. (a) Chemical structure of aTd, (b) SKH1-E hairless
mice and human skin samples treated with aTd or vehicle. Samples treated with aTd expressed fewer cyclobutane pyrimidine dimer (CPD) antibody–reactive
cells in the epidermis. Scale bar represents 20 microns on mouse skin and 100 microns on human. (c) Dorsal mouse skin treated with aTd versus vehicle. Harvest
times of 1, 8, and 24 hours after SSL shown. Fixed tissues were immunostained as noted previously and imaged with laser scanning single-photon confocal
microscopy. Scale bar represents 20 microns; (d) CPD formation in mouse epidermal keratinocytes was quantified and presented as the percentage of the total
imaged area reactive with CPD antibody as described in Lynch et al. (2008). In the vehicleþ SSL and aTdþ SSL groups, there was a significant difference in
thymine dimer formation at 1 and 8 hours, Po0.001. At 24 hours after UV irradiation, no significant difference was found between aTd- and vehicle-treated
samples, P40.05. There was no significant difference between aTd-treated mice at any time point, P40.05. Error bars denote SEM.
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Mice were euthanized 20 minutes after
UVB exposure and dorsal skins were
collected and fixed in the Zambonis
fixative for 24 hours. Thereafter, the
dorsal skins were transferred to a 20%
sucrose cryopreservative for long-term
storage. Tissues were cut on a Leica
cryostat at  24 1C and immunostained
with anti-CPD antibody, also referred to
as anti-thymine dimer antibody (KTM53
monoclonal cat. no. MC-062, Kamiya
Biomedical, Seattle, WA). Samples were
imaged using conventional epifluores-
cence, and the immunoreactivity of
the antibody with thymine dimers in
the epidermis was evaluated. Using
identical acquisition settings, samples
were photographed in three separate
fields of view. We observed a reduction
in epidermal thymine dimer formation
at 20 minutes after UVB exposure in
dorsal mouse skin and human abdom-
inal skin explants (Figure 1b) treated
with aTd.
TIME COURSE OF DIMER
FORMATION
The time course of thymine dimer for-
mation in the SKH1-E hairless mouse
model was evaluated using a single
acute dose of UVB (180 mJ cm2
UVB) given as solar-simulated light
(SSL). Q-PANEL solar-simulating bulbs
(Q-Lab, Westlake, OH) were chosen as
they closely resemble natural sunshine
and emit both UVA and UVB; however,
only the UVB output was metered here.
Mouse dorsal skins were harvested at 1,
8, and 24 hours after irradiation follow-
ing the same topical treatment regimen
as previously described. Samples were
sectioned, the percentage of thymine
dimers in the epidermis was determined
using histomorphometric analysis proto-
cols for mouse skin, and imaged using
laser scanning single-photon confocal
microscopy (LSCM, white color,
Olympus 63XOBJ at 2Z) following
established protocols (Lynch et al.,
2008). Thymine dimer levels in the
aTd-treated groups were significantly
reduced compared with the control
tissue at 1 and 8 hours, Po0.001.
There was no significant difference in
dimer levels between the control and
treated groups at 24 hours, P40.05. No
significant difference within the aTd-
treated groups was observed (Figure 1d).
CHRONIC EXPOSURE
The long-term risk of chronic sun expo-
sure, with and without topical aTd
protection, was subsequently examined.
Mice received topical treatments with
aTd or cream vehicle as described ear-
lier and were irradiated with SSL five
times per week for 13 weeks and mon-
itored for UV-induced tumors for the
next 17 weeks using standards
explained by de Gruil (de Gruil and
van der Leun, 1991). The initial dose,
35 mJ cm2, of UVB represented 70%
edema dose (Pentland et al., 1999) and
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Figure 2. Acyclothymidine dinucleoside (aTd) topical treatment and chronic exposure to solar-simulated light (SSL). (a) Representative images of mice at 30
weeks (n¼ 30). Animals in the vehicle- and aTd-treated groups that did not receive SSL showed no UV-induced tumors or other adverse skin conditions. Animals
in the vehicleþ SSL group exhibited larger tumors that multiplied more rapidly than aTd-treated groups. (b) At week 20 of the study period, 80% of mice in the
vehicleþ SSL group exhibited a measurable tumor burden versus 40% of aTd-treated mice at the same time point, Po0.0047. Significant reduction continued
through week 10, after UV irradiation, to week 23 of the study, noted as * on graph. At week 30 of the study, week 17, after UV irradiation, 8% of the mice in the
aTd-treated group remained tumor free compared with no tumor-free mice in the vehicleþ SSL group, two-tailed t-test P¼ 0.076. (c). There was a significant
difference in the ratio between small and large tumors between the control and aTd-treated groups, P¼ 0.0006.
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was increased by 10% per week until a
final dose of 69mJcm 2 was achieved.
That dose was maintained for the
remainder of the irradiation sessions.
Mice were photographed once weekly
from 14 to 30 weeks. All mice were
euthanized at the end of 30 weeks, and
the dorsal skin was collected as described
earlier. Mice with tumors exceeding the
size of 1ml were euthanized earlier as
necessary in accordance with IACUC
policies for tumor burden. Representa-
tive images of mice at week 30 are
shown in Figure 2a. In the absence of
SSL, neither cream vehicle nor aTd treat-
ments produced adverse skin conditions
(Figure 2a). Tumor onset occurred 4
weeks after the last irradiation session
(week 17 of study) in both groups, and
multiplicity was significantly slower in
weeks 20 to 23 in the aTd-treated group,
Po0.05 (Figure 2b). By week 22 (week 9,
post UV), 100% of the mice in the cream
vehicleþ SSL group were carrying UV-
induced tumors. This was significantly
higher compared with the aTd-treated
group, which showed 64% of mice carry-
ing tumors at the same time point
(Po0.0003). Tumor size and numbers
were recorded at 30 weeks, and the
percentage of larger tumors was obser-
ved to be higher in the cream vehicle only
group, P¼ 0.0006 (Figure 2c). Differ-
ences in the size of tumor may be
attributed to a faster growth rate in the
vehicle-treated group, leading to advan-
ced severity of the tumor (de Gruil and
van der Leun, 1991). After 30 weeks, of
the mice that exhibited tumors in the aTd
group, there were 18% fewer tumors as
compared with the vehicle-treated group,
P¼ 0.18, and 27% fewer tumors overall
in the aTd-treated group, P¼ 0.08.
In this study, we have demonstrated
that aTds act as structural mimetics of
DNA and its topical treatment resulted
in significant DNA photoprotection in
both mouse and human skin exposed to
acute UVB and reduced UV-induced
skin tumor development in chronic
UV-irradiated mice. We continue to
work on delineating the mechanistic
aspects of the observed DNA photo-
protection, including a possible role in
DNA repair. Concomitantly, we are
examining aTd’s role in skin anti-aging
based on chronic UV studies.
All studies involving mice were
reviewed and approved by the Univer-
sity of Minnesota Institutional Animal
Care and Use Committee (IACUC).
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Downregulation of SAMHD1 Expression Correlates with
Promoter DNA Methylation in Se´zary Syndrome Patients
Journal of Investigative Dermatology (2014) 134, 562–565; doi:10.1038/jid.2013.311; published online 22 August 2013
TO THE EDITOR
Although only about 15% of non-Hodg-
kin lymphomas are T-cell lymphomas,
the treatment of this subset of neoplasms
remains a significant challenge in the
field of hematological cancers owing to
unclear mechanisms regulating malig-
nant T-cell growth. Cutaneous T-cell
lymphoma (CTCL) identifies a group of
extranodal T-cell lymphomas character-
ized by the infiltration of malignant
CD4þ T cells in the skin (Wong et al.,
2011). Se´zary syndrome (SS) is an
aggressive subtype of CTCL defined byAccepted article preview online 24 July 2013; published online 22 August 2013
Abbreviations: CTCL, cutaneous T-cell lymphoma; PBMCs, peripheral blood mononuclear cells;
SAMHD1, sterile alpha motif and hemidesmosome domain containing protein 1; SS, Se´zary syndrome
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